Much-efficient and cost-effective manufacturing of antibody biotherapeutics employing integrated negative chromatography technology

采用集成负色谱技术高效且经济地生产抗体生物治疗药物

• 批准号: 102150
• 金额: $ 91.81万
• 依托单位: UCB CELLTECH
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2015
• 资助国家: 英国
• 起止时间: 2015 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=102150
• 关键词: Much; efficient; cost; effective; manufacturing

The current platform antibody purification process deployed in the bioprocesing industry becomes less efficient and less cost-effective to match with high titre upstream technologies. Based on previous feasibility studies using model antibodies, the key aim and objective of this project is to investigate negative chromatography based technologies using real industrial feedstocks to dramatically improve the overall process efficiency issue as described above. The market size in the downstream biopharmaceutical processing sector is ca $3 - 5 billions and it is a global market to play. The successful outcomes of this project will bring enormous potential cost benefits to the industry.

目前在生物加工行业中部署的平台抗体纯化工艺变得效率较低且成本效益较低，无法与高滴度上游技术相匹配。基于先前使用模型抗体的可行性研究，本项目的主要目的和目标是研究使用真实的工业原料的基于负色谱的技术，以显著改善如上所述的整体工艺效率问题。下游生物制药加工行业的市场规模约为30 - 50亿美元，这是一个全球市场。该项目的成功将为该行业带来巨大的潜在成本效益。